Big Returns For Oncology Investors
This article was originally published in Start Up
Executive Summary
Patently successful and promising immune-oncology technologies, large markets, and attractive returns have factored into impressive investments in companies with cancer-targeting drugs or technologies. A five-plus-year study of fundraising for biopharma, medtech, and diagnostics companies, using deal data from Informa’s Strategic Transactions, indicates strong and steadily building investor confidence in the segment.